Baird’s Global Pharmaceutical Services team continues to display significant deal flow and transaction velocity closing 18 transactions in the last 24 months. Our recent M&A and ECM transaction activity spans the pharma services sector including discovery services, pre-clinical and clinical CRO, CDMO, commercialization, pharma IT and associated technologies.

Baird's commitment to pharma services is displayed in our expanded global team, which now includes dedicated bankers in the US, UK and Europe with broader healthcare reach across Asia. Our global presence is paying dividends for our clients too as ~40% of our recent transactions were cross-border or international deals. 

Our Global Investment Banking and Financial Sponsor coverage provide an extensive network of relationships among active Healthcare acquirers, partners and investors. This has yielded an approximate 40% strategic buyer / 60% private equity buyer on Baird pharma services sellsides since 2020.

Select Recent Transactions